Kornimate/medical-research-clean huggingface dataset:
echo systemic sclerosis

Conditions: Systemic Sclerosis; Gougerot Sjogren Syndrome; Sicca-Asthenia-Polyalgia Syndrome

Summary: systemic sclerosis is an autoimmune connective tissue disease with undefined etiology and characterized by progressive fibrosis of the skin and major organs. dry eyes and / or buccal syndrome is commonly reported in patients with systemic sclerosis. goujerot-sjogren syndrome is a chronic autoimmune disorder that is characterized by dryness of the eyes (xerophthalmia) and / or mouth (xerostomia). it may be primary or secondary to another connective tissue disease (such as lupus, rheumatoid arthritis or other). several criteria have been validated to classify the ss but require a labial salivary gland biopsy, invasive act which complications can sometimes be reported (hematoma, lip sensory defect). several scores based on the evaluation of the ultrasound homogeneity of the salivary glands were developed but no studies have evaluated ultrasound abnormalities of salivary glands in patients with systemic sclerosis.

descriptive explorative study of three population showing sicca symptoms (systemic sclerosis, gougerot-sjogren syndrome, sicca-asthenia-polyalgia syndrome). patient will be enrolled in the rheumatology department of university hospital of clermont-ferrand (france). salivary glands ultrasonography will be performed on all patients enrolled by the same expert and blinded to the diagnosis of the patient. echostructure of the two salivary glands will be graded 0 to 4 and the size calculated.

Eligibility criteria:
inclusion criteria: * systemic sclerosis diagnosis established by a rheumatologist and met acr 2012 criteria * or primary gougerot-sjogren patient who met american-european consensus group (aecg) classification criteria. * or patient presenting a sicca syndrome but not met gougerot-sjogren criteria exclusion criteria: * history of radiotherapy on face and neck * infection such as vih or hepatitis c * sarcoidosis * amylosis * wearing contact lenses * hyper igg4 syndrome

Keywords: salivary glands ultrasonography systemic sclerosis gougerot sjogren syndrome sicca syndrome
effect of intravenous acetadote on incidence of contrast induced nephropathy

Conditions: Nephropathy

Summary: in patients undergoing coronary angiography, the incidence of contrast induced nephropathy(cin)varies widely and ranges from \< 5% in the lowest risk patients, to nearly 50% in the highest risk patients. prior data has shown oral n-acetyl cysteine (nac) to be effective in reducing the incidence of cin.due to extensive first pass metabolism, the bioavailability of oral nac is poor and ranges from 4%-10%. we hypothesize that the incidence of cin will be reduced in patients with acs who undergo pci by the prophylactic administration of intravenous nac. this is a prospective, randomized, double-blind, placebo-controlled single center clinical trial designed to evaluate the effects of intravenous nac on patients with acute coronary syndromes (acs)undergoing coronary angiography and/or percutaneous coronary intervention (pci). the medication acetadote is provided by cumberland pharmaceuticals inc (www.cumberlandpharma.com). patients will be excluded if they have end-stage renal disease requiring dialysis,known hypersensitivity to nac or a history of life-threatening contrast reaction. primary end-point is incidence of cin. secondary end-points are in-hospital mortality,30-day mortality,duration of hospitalization and change in serum cystatin c level.


Eligibility criteria:
inclusion criteria: 1. 18 years of age or older. 2. hospitalized with a primary diagnosis of acute coronary syndrome. 3. scheduled for coronary angiography or intervention during the current hospitalization. exclusion criteria: 1. have end-stage renal disease (esrd) requiring dialysis. 2. have a known hypersensitivity to nac. 3. have a history of life-threatening contrast reaction. -

Keywords: contrast nephropathy intravenous n-acetlycysteine
vitamin d deficiency in subjects with chronic hepatitis c compared to healthy volunteers

Conditions: Chronic Hepatitis C

Summary: the objective of this study is to assess the prevalence of vitamin d deficiency in patients with chronic hepatitis c compared to a matched control group of healthy individuals in the sioux falls area. it is the hypothesis of this study that vitamin d deficiency is more common in patients with chronic hepatitis c compared to the healthy control group.

in this study, we will measure vitamin d levels in patients with chronic hepatitis c and healthy individuals. this study will be important to assess vitamin d inadequacy in patients with chronic hepatitis c and healthy individuals in this area.

Eligibility criteria:
inclusion criteria for study group: * men and women between the ages of 25 and 55 * diagnosis of chronic hepatitis c exclusion criteria for study group: * taking a vitamin d supplement (by itself or as part of a multivitamin), a calcium supplement and/or biphosphonates * has acute hepatitis c infection * has chronic hepatitis b infection * had gastric bypass surgery * has chronic kidney disease inclusion criteria for control group: * men and women between the ages of 20 and 60 * has a body mass index (bmi) between 20 and 35 exclusion criteria for study group: * taking a vitamin d supplement (by itself or as part of a multivitamin), a calcium supplement and/or biphosphonates * has any significant illness or medical problem that is not under control or being controlled by medication * history of hepatitis or abnormal liver chemistry tests * history of intravenous drug use

Keywords: hepatitis c chronic hepatitis c vitamin d vitamin d deficiency
vitamin b12 for aromatase inhibitors musculoskeletal symptoms

Conditions: Relief of Joint Pain

Summary: significant aromatase inhibitor-associated toxicity, affects as many as 50% of patients with breast cancer leading to early discontinuation of this life-saving cancer treatment. no effective pharmacologic therapy has yet been identified for management of these symptoms, as many patients do not experience relief of symptoms with analgesic therapy. vitamin b12, whether as injection or oral forms, has been used as a naturopathic product to provide relief for joint pain caused by arthritis. this effect has not been studied in the setting of aromatase inhibitor-associated musculoskeletal symptoms (aimss).

primary objectives: a. to assess whether daily oral vitamin b12 decreases average joint pain in women with aromatase inhibitor-associated musculoskeletal symptoms (aimss), as measured at baseline, 6 weeks and at 12 weeks by the modified brief pain inventory short form (bpi-sf). secondary objectives: 1. to investigate whether daily vitamin b12 improves functional quality of life as measured by the functional assessment of cancer therapy-endocrine scale (fact-es); 2. to explore the impact of treatment on serum inflammatory cytokine levels (c reactive protein) with 12 weeks of treatment between baseline and 12 weeks.

Eligibility criteria:
inclusion criteria: * sign informed consent and pain level \> 4 in the bpi scale, * stage i-iii exclusion criteria: * \<18 yrs * stage iv * bpi score \<4 * zubrod score \>2

Keywords: aromatase inhibitor breast cancer arthralgia musculoskeletal symptoms joint pain
glucose metabolism disorders and metabolic syndrome before and after primary hip and knee replacement

Conditions: Hyperglycemia; Hypercholesterolemia; Persistent Postoperative Pain; Hip Replacement; Knee Replacement

Summary: osteoarthritis patients undergoing primary hip and knee replacement are followed-up and changes in their glucose metabolism and other metabolic parameters (obesity, cholesterol levels) are examined. persistent postoperative pain is examined as secondary outcome.

glucose metabolism disorders (diabetes and pre-diabetes) and metabolic syndrome are common in joint replacement recipients. improved physical activity following joint replacement could lead to better glucose control in diabetes and ameliorate impaired glucose and cholesterol levels. in this study patients previously recruited to "perioperative hyperglycaemia in primary total hip and knee replacement" study are being followed-up for one year in order to analyze if joint replacements have an effect on these metabolic abnormalities. in addition, the effect of glucose metabolism disorders on occurrence of persistent pain after surgery is analyzed.

Eligibility criteria:
inclusion criteria: * primary hip and knee replacement for osteoarthritis * enrolled previously into study nct01021826 exclusion criteria: * arthritis other than osteoarthritis (based on study nct01021826) * medication affecting glucose metabolism (excl. antidiabetic agents) (based on study ntc01021826) * died before follow-up phase * did not undergo the planned hip or knee replacement

Keywords: glucose metabolism disorders metabolic syndrome joint replacement osteoarthritis
a study of avastin (bevacizumab) in combination with gemcitabine with or without cisplatin in first-line treatment of elderly patients with non-small cell lung cancer

Conditions: Non-Squamous Non-Small Cell Lung Cancer

Summary: this 2 arm study will evaluate the efficacy and safety of avastin + gemcitabine, and avastin + gemcitabine + attenuated doses of cisplatin, as first line treatment in elderly patients with non-squamous non-small cell lung cancer. patients will be randomised to receive either avastin 7.5mg/kg iv on day 1 + gemcitabine 1200mg/m2 on days 1-8 of each 3 week cycle, or avastin 7.5mg/kg iv on day 1 + cisplatin 60mg/m2 on day 1 + gemcitabine 1000mg/m2 on days 1-8 of each 3 week cycle. after 6 cycles of combination therapy, all patients will continue to receive avastin monotherapy. the anticipated time on study treatment is until disease progression, and the target sample size is \<100 individuals.


Eligibility criteria:
inclusion criteria: * adult patients, \>=70 years of age; * inoperable, locally advanced, metastatic non-squamous non-small cell lung cancer; * \>=1 measurable lesion; * ecog performance status 0-1. exclusion criteria: * neoadjuvant/adjuvant chemotherapy within 6 months prior to enrollment; * radical radiotherapy with curative intent within 28 days prior to enrollment; * history of \>=grade 2 hemoptysis in 3 months prior to enrollment; * evidence of cns metastases; * current or recent (within 10 days of first dose of avastin)use of aspirin (\>325 mg/day)or full dose anticoagulants or thrombolytic agents for therapeutic purposes.
study of safety & efficacy of the combination of ljm716 & byl719 in patients with previously treated esophageal squamous cell carcinoma (escc)

Conditions: Esophageal Squamous Cell Carcinoma

Summary: to study the safety and efficacy of the combination of ljm716 and byl719 against currently available treatments of physician's choice in previously treated esophageal squamous cell carcinoma patients.

the study design included a phase 1b dose escalation portion to define the maximum tolerated dose (mtd)/recommended phase 2 dose (rp2d) for the combination of ljm716 and alpelisib, followed by an open-label, randomized phase 2 part to compare anti-tumor activity of ljm716-alpelisib combination versus physician's choice of second-line therapy (paclitaxel, docetaxel, irinotecan). however, the phase 2 part was not conducted as the study was terminated early due to limited anti-tumor activity with ljm716-alpelisib combination observed in phase 1b.

Eligibility criteria:
inclusion criteria: * histologically confirmed esophageal squamous cell carcinoma (escc) * no more than one prior chemotherapy regimen for recurrent or metastatic escc (for phase ii only). * progression during or after platinum-based therapy for recurrent or metastatic escc, or recurrence within 6 months of platinum-based chemotherapy or chemoradiotherapy for localized disease. exclusion criteria: * patients who received prior phosphoinositide-3-kinase (pi3k) inhibitor or anti-receptor tyrosine-protein kinase erbb-3 (erbb3 or her3) antibody treatment, including bi-specific antibodies with her3 as one of the targets (patients with prior exposure to pertuzumab or epidermal growth factor receptor (egfr)-targeted agents are eligible) * patients who do not have an archival or fresh tumor sample (or sections of it) available or readily obtainable. * patients with central nervous system (cns) metastatic involvement. * patients who have received prior systemic anti-cancer treatment, such as cyclical chemotherapy or biological therapy within a period of time that is shorter than the cycle length used for that treatment (e.g. 6 weeks for nitrosourea, mitomycin-c) prior to starting study treatment. * patients who have received definitive radiotherapy ≤ 4 weeks prior to starting study drug, who have not recovered from side effects of such therapy and/or from whom ≥ 30% of the bone marrow was irradiated. * other protocol-defined inclusion/exclusion criteria may apply.

Keywords: esophageal cancer
fully disposable patient-specific instrumentation

Conditions: Osteoarthritis,Knee

Summary: to evaluate the lower limb alignment following total knee arthroplasty (tka) performed with fully disposable patient-specific instrumentation versus conventional, versus patient specific instrumentation.

the investigators performed a controlled multicenter trial comparing the clinical and radiologic results and resources consumption of primary tka using patient-specific cutting guides (pscg) versus conventional instrumentation (ci), and compared the results to those obtained with a fully disposable patient-specific instrumentation (pscg-d).

Eligibility criteria:
inclusion criteria: * patients aged between 18 and 85 years * able to understand information * affiliated to social security exclusion criteria: * active or suspected sepsis * tumor around the knee * previous partial or total knee replacement * extra-articular deformation requiring osteotomy around the knee in conjunction with tka * social situation that could impair follow-up
efficacy of high-flow nasal oxygen in preventing hypoxia during gastrointestinal endoscopy: a retrospective cohort study

Conditions: Hypoxia

Summary: during painless gastroscopy, the occurrence of hypoxia is a critical concern, especially under intravenous anesthesia using propofol. this study aimed to investigate the incidence of hypoxia during painless gastroscopy and evaluate preventive measures.

from june 15 th 2023 to august 15th 2023, 900 patients who underwent elective gastroscopy in the renji hospital, shanghai jiao tong university school of medicine were selected. they were divided into the high flow nasal cannula oxygen group and the conventional nasal cannula oxygen group by oxygen inhalation. patient demographics, mallampati class, and other relevant factors were compared between the two groups. primary outcomes included the incidence hypoxia (spo2 \< 90%), while secondary outcomes included subclinical respiratory depression, and adverse events related to nasal oxygen cannula.

Eligibility criteria:
inclusion criteria： * patients aged 18 to 70 * undergoing painless gastroscopy under intravenous anesthesia exclusion criteria： * severe respiratory disease * history of nasal bleeding or mucosal injury * emergency cases * pregnant or lactating female

Keywords: high flow nasal cannula oxygen
the effect of peri-operative adjunctive probiotics on immunological markers in cases of prosthetic joint infection of the hip and knee

Conditions: Prosthetic-joint Infection

Summary: the purpose of this study is to determine whether probiotics in addition to standard of care (soc) can improve immunological markers following treatment for prosthetic joint infection (pji). the study aims to determine whether probiotics in addition to soc decrease immunological markers following treatment for pji, improve medical and surgical complications and mortality in patients with pji, and lead to improved gastrointestinal (gi)-specific patient reported outcomes measures (proms) in patients with pji.


Eligibility criteria:
inclusion criteria: * patients ages 18-90 years of age. * diagnosis of pji based upon musculoskeletal infection society (msis) criteria * planned treatment with surgical debridement, antibiotics, implant retention (dair), single- and two-stage revision total joint arthroplasty (tja) for pji with an anticipated plan for eventual discontinuation of oral/iv antibiotics. * patients with prior pji in the same joint that has recurred. * patients who understand the benefits and risks associated with taking a probiotic and are willing and able to provide informed consent. exclusion criteria: * fungal pji. * inflammatory bowel disease, diverticulitis, history of intestinal surgery, or gastrointestinal issue where there is concern for gut integrity. * severe acute gastrointestinal diseases (active bowel leak, acute colitis, acute pancreatitis). * active endocarditis. * history of pancreatitis * history of intolerance to probiotics. * patients that are pregnant or lactating. * immunocompromised patients and patients with immunosuppressive conditions (uncontrolled hiv, chemotherapy for cancer treatment, stem cell transplantation, immunosuppressive medications for solid organ transplant, systematic corticosteroid use, immunosuppressive medications for autoimmune dysfunction, and neonates). * patients who are critically ill. * revision tja for aseptic reasons.
quantitative muscle ultrasound as a marker of progression in children with muscular diseases

Conditions: Inflammatory Myopathy; Duchenne Muscular Dystrophy

Summary: the aim of our study is to assess skeletal muscle structural status in children with inflammatory myositis and duchenne muscular dystrophy using musculoskeletal ultrasound and to perform a longitudinal follow up of these changes over 2 years and to assess the relation between these findings with clinical parameters, functional scales, biochemical and electromyographic tests.

this study will be carried out on two groups: • group (i): fifty children diagnosed to have duchenne muscular dystrophy and inflammatory myositis. group (ii): including 20 healthy children matching age and sex as control group. patients will be subjected to (a) clinical evaluation 1. complete history taking. 2. thorough clinical examination. 3. body mass index (bmi) assessment. 4. quantitative muscle strength tests 5. functional grading 6. childhood myositis assessment scale. 7 (b) laboratory assessment: all patients will be subjected to the following measurements: 1. serum creatine kinase levels (ck). 2. serum lactate dehydrogenase levels 3. serum of liver enzymes (sgot\& sgpt) levels. (c) electromyographic (emg) assessment: (d) musculoskeletal ultrasound assessment (e) statistical analysis

Eligibility criteria:
inclusion criteria: * children with duchenne muscular dystrophy (dmd). diagnosis with dmd was established according to dmd diagnostic criteria (jennekens et al., 1991). * children with juvenile dermatomyositis (jdm) according to bohan and peter diagnostic criteria ( (bohan and peter, 1975). exclusion criteria: * patients with age less than 2 years were excluded from the study due to inability to perform manual muscle testing and functional scales. * if no final diagnosis could be established. * the presence of a concomitant illness that may result in peripheral neuropathy or myopathy.

Keywords: inflammatory myositis duchenne muscular dystrophy musculoskeletal ultrasound
exploratory study of the relationships between the biomarkers of inflammation, lipidome and insulin resistance and disorders of glycemic regulation in a cohort of insulin-resistant subjects due to excess weight or dunnigan's lipodystrophy

Conditions: Lipodystrophy; Dunnigan Syndrome

Summary: the objective of this work is to identify biomarkers of interest in patients with insulin resistance leading to early disorders of glycemic regulation. for this the investigators want to assay the insulin resistance marker insulin regulated amino peptidase serique (iraps), the plasma lipidome and inflammation markers in 2 populations of insulin-resistant subjects due to dunnigan's inherited lipodystrophy or overweight/obesity and insulin-sensitive subjects with or without a glycemic regulation disorder objectified during an oral induced hyperglycemia. the results of the iraps, lipidome and inflammation assays will be compared in insulin-resistant subjects, between normoglycemic, prediabetic and diabetic subjects. correlations will be made between these markers and the deterioration of glycemic regulation as well as with known insulin resistance parameters (homeostasis assessment model (homa), quantitative insulin-sensitivity check index (quicki),insulin sensitivity index (isi) matsuda).


Eligibility criteria:
inclusion criteria: * subjects with dunnigan's lipodystrophy or non-lipodystrophic insulin-resistant subjects or insulin-sensitive non-lipodystrophic subjects * major * subjects benefiting from metabolic exploration in the endocrinology, diabetology and nutrition department of the reunion university hospital. * subject benefiting from an oral glucose tolerance test (ogtt) during his follow-up in the endocrinology, diabetology and nutrition department of the reunion university hospital. * person affiliated or beneficiary of a social security scheme. * subject having been informed of the study in progress and having given their written consent. exclusion criteria: * pregnant woman * person under guardianship or curators or deprived of liberty